The new drug, developed by Novartis and MMV, isn't a malaria vaccine, but can help treat babies with the disease.

Malaria caused 597,000 deaths worldwide in 2023, with children under 5 accounting for 76 percent of all malaria deaths in the ...

The innovative vaccine delivery system can provide full course of immunisation - both initial and booster doses.

Oxford researchers have developed programmable microcapsules to deliver vaccines in stages, potentially eliminating the need ...

Key Takeaways A new malaria drug is approved for babies under 11 poundsThe treatment dissolves easily in breast milk and has ...

Novartis' Coartem Baby wins Swiss approval as the first malaria drug for newborns under 5 kg, offering safer dosing and ...

A mother holds her baby receiving a new malaria vaccine as part of a trial at the Walter Reed Project Research Center in ...

Novartis said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat ...

Novartis and a Swiss nonprofit have made history, scoring the world’s first approval for a medicine to treat babies who are ...

A team of scientists at the University of Oxford has developed an innovative vaccine delivery system that could allow a full course of immunization—both initial and booster doses—to be ...

Coartem Baby, which was cleared by health authorities in Switzerland, will fill an important gap in treatment. Novartis plans ...

By Maggie Fick and Jennifer Rigby LONDON (Reuters) -Drugmakers Bharat Biotech and GSK will cut the price of their malaria ...